Page last updated: 2024-12-04

picolinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

picolinic acid: iron-chelating agent that inhibits DNA synthesis; may interfere with iron-dependent production of stable free organic radical which is essential for ribonucleotide reductase formation of deoxyribonucleotides; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7206 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

picolinic acid : A pyridinemonocarboxylic acid in which the carboxy group is located at position 2. It is an intermediate in the metabolism of tryptophan. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1018
CHEMBL ID72628
CHEBI ID28747
SCHEMBL ID36055
MeSH IDM0096711

Synonyms (100)

Synonym
AC-2105
CHEBI:28747 ,
alpha-pyridinecarboxylic acid
2-picolinic acid
alpha-picolinic acid
TOS-BB-0927 ,
brn 0109595
nsc 21209
acide picolique [french]
nsc 171
pyridine-carboxylique-2 [french]
einecs 202-719-7
nicogamol
nikogamol
pyridine-2-carboxylic acid
nsc21209
OPREA1_485360
ai3-19242
o-pyridinecarboxylic acid
2-pyridinecarboxylic acid
nsc171
picolinic acid
2-pyridinecarboxylate
.alpha.-pyridinecarboxylic acid
nsc-171
98-98-6
2-pyridine carboxylic acid
2-carboxypyridine
2-picolinic acid, reagentplus(r), 99%
6PC ,
NCGC00165993-01
NCI60_001382
MLS001335932
smr000814709
MLS001335931
C9DF3EBC-98F0-4165-BE9A-92F8EE33CDBA
inchi=1/c6h5no2/c8-6(9)5-3-1-2-4-7-5/h1-4h,(h,8,9)
sioxpemlgupbbt-uhfffaoysa-
CHEMBL72628 ,
P0421
bdbm50000407
AKOS000119032
pyridinecarboxylic acid
NCGC00260499-01
dtxcid5011903
tox21_112282
tox21_202953
dtxsid7031903 ,
cas-98-98-6
HMS2232K05
STL164340
88161-53-9
32075-31-3
ccris 8307
unii-qzv2w997jq
acide picolique
qzv2w997jq ,
pyridine-carboxylique-2
5-22-02-00003 (beilstein handbook reference)
BP-13036
FT-0608336
AB00685
S6249
BP-21456
AM81303
SCHEMBL36055
NCGC00165993-02
tox21_112282_1
picolinic acid [mi]
PS-4253
picolic acid
pyridine-carboxylic acid
2-pyridine-carboxylic acid
2-pyridincarboxylic acid
pyridine carboxylic acid
2-picolic acid
2-pyridine carboxic acid
a-picolinic acid
pyridine-a-carboxylic acid
pyridinecarboxylic acid-(2)
W-100058
STR00111
picolinicacid
mfcd00006293
F2191-0113
CS-D1196
pcl 016
a-pyridinecarboxylic acid
phenyl-(2-pyridyl)acetonitrile
2-picolinic acid, vetec(tm) reagent grade, 98%
pyridinium 2-carboxylate
2-picolate
Z57968195
HY-I0660
SY001169
Q416682
BCP26613
picolinic-acid
picolinic acid (pcl 016)
EN300-18459

Research Excerpts

Overview

Picolinic acid (PIC) is a byproduct of tryptophan catabolism through the kynurenine pathway, with anabolic effects on bone in vivo and in vitro. It is a natural toxic pyridine derivative as well as an important intermediate used in the chemical industry.

ExcerptReferenceRelevance
"Picolinic acid (PIC) is a byproduct of tryptophan catabolism through the kynurenine pathway, with anabolic effects on bone in vivo and in vitro. "( Evaluating the toxicity of escalating dose of oral picolinic acid in Sprague-Dawley rats.
Bani Hassan, E; Bienvenu, JG; Doyle, N; Duque, G; Guillemin, GJ; Stent, A, 2021
)
2.32
"Picolinic acid (PA) is a natural toxic pyridine derivative as well as an important intermediate used in the chemical industry. "( PicR as a MarR Family Transcriptional Repressor Multiply Controls the Transcription of Picolinic Acid Degradation Gene Cluster
Cheng, M; He, J; Hong, Q; Jiang, Y; Qiu, J; Wang, X; Xu, S; Yan, X; Zhang, F; Zhang, Y, 2022
)
2.39
"Picolinic acid (PA) is a tryptophan metabolite endogenously produced in mammals."( Picolinic acid is a broad-spectrum inhibitor of enveloped virus entry that restricts SARS-CoV-2 and influenza A virus in vivo.
Agarwal, R; Biji, A; Das, S; Jeyasankar, S; Joy, CM; Kanojia, A; Kaur, S; Khatun, O; Narayan, R; Narayanan, S; Rajmani, R; Rani, P; Rao, DC; Satchidanandam, V; Shandil, RK; Sharma, M; Sharma, PR; Tripathi, S; Yadav, R, 2023
)
3.07
"Picolinic acid (PiA) is an endogenous metabolite of tryptophan that has been reported to possess a wide range of physiological actions. "( Large amounts of picolinic acid are lethal but small amounts increase the conversion of tryptophan-nicotinamide in rats.
Fukuwatari, T; Shibata, K, 2014
)
2.18
"Picolinic acid (PIC) is an endogenous metabolite of the kynurenine pathway and a chelating agent added to dietary supplements."( Influence of picolinic acid on seizure susceptibility in mice.
Cioczek-Czuczwar, A; Czuczwar, P; Parada-Turska, J; Turski, WA, 2017
)
1.55
"Picolinic acid (PA) is a catabolite of tryptophan, known to exert costimulatory activities on macrophages and expected to act on transcriptional elements within HRE3x-Tk promoter."( Antifungal activity of macrophages engineered to produce IFNgamma: inducibility by picolinic acid.
Blasi, E; Colombari, B; Mucci, A; Neglia, R; Pastorino, S; Varesio, L, 2003
)
1.27

Toxicity

ExcerptReferenceRelevance
"These data demonstrate a lack of toxicity of trivalent Cr, at levels that are on a per kg basis, several thousand times the upper limit of the estimated safe and adequate daily dietary intake for humans."( Lack of toxicity of chromium chloride and chromium picolinate in rats.
Anderson, RA; Bryden, NA; Polansky, MM, 1997
)
0.3
"Trivalent chromium is an essential trace element that is considered safe when ingested in normal quantities."( Chromium picolinate toxicity.
Cerulli, J; Gauthier, I; Grabe, DW; Malone, M; McGoldrick, MD, 1998
)
0.3
"Cost limitations, adverse effects or lack of efficacy limit the use of current topical therapies in mild to moderate acne vulgaris."( A pilot study of the safety and efficacy of picolinic acid gel in the treatment of acne vulgaris.
Anadkat, MJ; Heffernan, MP; Nelson, MM, 2007
)
0.6
" No serious adverse events or clinically significant changes in laboratory values were noted."( A pilot study of the safety and efficacy of picolinic acid gel in the treatment of acne vulgaris.
Anadkat, MJ; Heffernan, MP; Nelson, MM, 2007
)
0.6
"Results from this study suggest that 10% picolinic acid gel applied twice daily may be safe and effective in the treatment of mild to moderate acne vulgaris."( A pilot study of the safety and efficacy of picolinic acid gel in the treatment of acne vulgaris.
Anadkat, MJ; Heffernan, MP; Nelson, MM, 2007
)
0.87
" Dams were sacrificed on GD 17, and their litters were examined for adverse effects."( Comparison of the potential for developmental toxicity of prenatal exposure to two dietary chromium supplements, chromium picolinate and [Cr3O(O2CCH2CH3)(6(H2O)3]+, in mice.
Ankareddi, I; Bailey, MM; Bushman, J; Hood, RD; Jernigan, PL; Rasco, JF; Sturdivant, J; Townsend, MB; Vincent, JB, 2008
)
0.35
" Each male was mated with two females, which were sacrificed on gestation day 17, and their litters were examined for adverse effects."( Potential of chromium(III) picolinate for reproductive or developmental toxicity following exposure of male CD-1 mice prior to mating.
Bailey, MM; Briggins, F; Di Bona, KR; Goodwin, C; McAdory, D; Rasco, JF; Rhodes, NR; Vincent, JB, 2011
)
0.37
" The results showed that no pathological, toxic feces and urine changes were observed in clinical signs of parental and fetal rats in chromium malate groups."( Evaluation of the Reproductive Toxicity, Glycometabolism, Glycometabolism-Related Enzyme Levels and Lipid Metabolism of Chromium Malate Supplementation in Sprague-Dawley Rats.
Bao, Y; Feng, W; Huang, J; Mao, G; Wang, W; Wu, X; Yang, L; Zhang, W; Zhao, T; Zhou, Z, 2015
)
0.42
"the use of statin to lower blood cholesterol is often associated with bothersome adverse effects such as myopathy and liver dysfunction."( Safety and Efficacy of NC120 for Improving Lipid Profile: A Double Blind Randomized Controlled Trial.
Hudyono, J; Nafrialdi, N; Setiawati, A; Suyatna, FD, 2019
)
0.51
" Rats receiving lower doses (125 or 250 mg/kg/day) of PIC completed treatment course without apparent clinical adverse events."( Evaluating the toxicity of escalating dose of oral picolinic acid in Sprague-Dawley rats.
Bani Hassan, E; Bienvenu, JG; Doyle, N; Duque, G; Guillemin, GJ; Stent, A, 2021
)
0.87

Pharmacokinetics

ExcerptReferenceRelevance
"3 pharmacokinetic calculating program (China Pharmaceutical University Medicine Center) was used to calculate the pharmacokinetic parameters."( Pharmacokinetics and bioavailability of chromium malate and its influence on trace metals absorption after oral or intravenous administration.
Chen, Y; Ding, Y; Feng, W; Feng, Y; Li, F; Li, Q; Mao, G; Wang, W; Wu, X; Yang, L; Zhao, T,
)
0.13

Compound-Compound Interactions

ExcerptReferenceRelevance
"We studied the in vitro and in vivo antimicrobial activities of picolinic acid (PA) in combination with the antiprotozoal drug quinacrine against intramacrophage Mycobacterium avium complex (MAC)."( Activity of picolinic acid in combination with the antiprotozoal drug quinacrine against Mycobacterium avium complex.
Shimizu, T; Tomioka, H, 2006
)
0.95

Bioavailability

ExcerptReferenceRelevance
" Picolinic acid, a metabolite of tryptophan, forms stable complexes with transitional metal ions, which results in an improved bioavailability of the metal ion chromium."( The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects.
Evans, GW; Geller, J; Press, RI, 1990
)
1.19
" But the higher bioavailability of zinc in human milk should not only be attributed to the presence of citrate."( [Effect of different concentrations of various zinc complexes (picolinate, citrate, 8-hydroxyquinolate) in comparison with sulfate on zinc supply status in rats].
Kirchgessner, M; Roth, HP, 1983
)
0.27
" A pharmacokinetic model was used to estimate the bioavailability of Cr from ingested Cr picolinate using known distribution patterns and elimination rates of Cr by humans."( Urinary excretion of chromium by humans following ingestion of chromium picolinate. Implications for biomonitoring.
Finley, BL; Gargas, ML; Norton, RL; Paustenbach, DJ,
)
0.13
" The greater bioavailability of CrPic compared with other forms of Cr (e."( Clinical studies on chromium picolinate supplementation in diabetes mellitus--a review.
Broadhurst, CL; Domenico, P, 2006
)
0.33
"The bioavailability of chromium from Cr-picolinate (CrPic(3)) and Cr-chloride (CrCl(3)) was studied in rats using (51)Cr-labelled compounds and whole-body-counting."( Absorption, excretion and retention of 51Cr from labelled Cr-(III)-picolinate in rats.
Fischer, R; Kottwitz, K; Laschinsky, N; Nielsen, P, 2009
)
0.35
" This study was aimed at assessing the pharmacokinetics and bioavailability of chromium malate and influence on trace metals absorption in rats."( Pharmacokinetics and bioavailability of chromium malate and its influence on trace metals absorption after oral or intravenous administration.
Chen, Y; Ding, Y; Feng, W; Feng, Y; Li, F; Li, Q; Mao, G; Wang, W; Wu, X; Yang, L; Zhao, T,
)
0.13
"The results showed that mean retention time (MRT) in chromium malate group was significantly prolonged and the area under the curve (AUC) and relative bioavailability of chromium malate (male) group were significant increase compared to chromium picolinate group."( Pharmacokinetics and bioavailability of chromium malate and its influence on trace metals absorption after oral or intravenous administration.
Chen, Y; Ding, Y; Feng, W; Feng, Y; Li, F; Li, Q; Mao, G; Wang, W; Wu, X; Yang, L; Zhao, T,
)
0.13
" The objective of this study was to measure the Fe bioavailability of Fe picolinate in a complementary fruit yogurt."( The bioavailability of iron picolinate is comparable to iron sulfate when fortified into a complementary fruit yogurt: a stable iron isotope study in young women.
Beaumont, M; Dubascoux, S; Grathwohl, D; Groulx, K; Guignard, LF; Habeych, E; Kastenmayer, P; Moretti, D; Richoz, J; Sabatier, M; Zeder, C; Zimmermann, MB, 2020
)
0.56
"The bioavailability of Fe picolinate was determined using stable iron isotopes in a double blind, randomized cross-over design in non-anemic Swiss women (n = 19; 25."( The bioavailability of iron picolinate is comparable to iron sulfate when fortified into a complementary fruit yogurt: a stable iron isotope study in young women.
Beaumont, M; Dubascoux, S; Grathwohl, D; Groulx, K; Guignard, LF; Habeych, E; Kastenmayer, P; Moretti, D; Richoz, J; Sabatier, M; Zeder, C; Zimmermann, MB, 2020
)
0.56
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The form of chromium (Cr) is an important factor that influences its bioavailability and potential toxicity, while the difference of Cr bioaccumulation between organic and inorganic Cr has been rarely investigated."( Bioaccumulation of dietary CrPic, Cr(III) and Cr(VI) in juvenile coral trout (Plectropomus leopardus).
Fu, Q; Guo, Z; Li, Y; Wei, L; Xiao, J; Zhang, P, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" Type of insulin, frequency of insulin administration, and diet were kept constant, and insulin dosage was adjusted, as needed, to maintain optimal control of glycemia."( Oral chromium picolinate and control of glycemia in insulin-treated diabetic dogs.
Kirk, CA; Nelson, RW; Schachter, S,
)
0.13
" The CrPic supplementation consisted of a 500 ug dosage taken once per day."( The effect of chromium picolinate on muscular strength and body composition in women athletes.
Adams, GM; Laguna, PL; Livolsi, JM, 2001
)
0.31
" The first was a time-course study in which animals were administered single doses of 50 mg/kg of Cr3+ picolinate and the second a dose-response study in which animals were given either 20 or 50 mg/kg Cr3+ picolinate versus vehicle alone via the intra-peritoneal route."( Effects of treatment with chromium picolinate on peripheral amino acid availability and brain monoamine function in the rat.
Franklin, M; Odontiadis, J, 2003
)
0.32
"A validated high performance liquid chromatographic method was developed for the determination of chromium picolinate in pharmaceutical dosage forms."( A validated method for analysis of chromium picolinate in nutraceuticals by reversed phase high performance liquid chromatography.
Aboul-Enein, HY; Hoenen, H; Koll, M, 2005
)
0.33
" The highest variability of DNA-damage was monitored under the prolonged treatment with high dosage of CrPic."( Chromium-picolinate therapy in diabetes care: individual outcomes require new guidelines and navigation by predictive diagnostics.
Golubnitschaja, O; Schild, HH; Yeghiazaryan, K, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
MALDI matrix materialA compound used to form the matrix for MALDI (matrix-assisted laser desorption/ionization) mass spectrometry. MALDI matrix materials are crystalline compounds with a fairly low molecular weight, so as to allow facile vaporization, have strong absorption at UV or IR wavelengths (to rapidly and efficiently absorb laser irradiation), generally contain polar groups (enabling them to be used in aqueous solutions) and are frequently acidic (so assisting ionisation of the compound being studied, which is contained within the matrix material).
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyridinemonocarboxylic acidA monocarboxylic acid in which the carboxy group is attached to a pyridine (or substituted pyridine) ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Kynurenine pathway and links to cell senescence2024
Biochemical pathways: part I0466
Tryptophan metabolism2342

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency50.11870.044717.8581100.0000AID485294
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency3.98110.631035.7641100.0000AID504339
phosphopantetheinyl transferaseBacillus subtilisPotency25.11890.141337.9142100.0000AID1490
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency7.76190.01237.983543.2770AID1645841
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency2.48820.001530.607315,848.9004AID1224841
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency2.81840.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.56230.035520.977089.1251AID504332
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency0.01510.057821.109761.2679AID1159526
flap endonuclease 1Homo sapiens (human)Potency79.43280.133725.412989.1251AID588795
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency14.12540.050127.073689.1251AID588590
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency14.12540.075215.225339.8107AID485360
gemininHomo sapiens (human)Potency13.99430.004611.374133.4983AID624296; AID624297
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase Aeromonas hydrophilaKi333.54004.50005.10005.7000AID323621; AID323622; AID323623; AID323624; AID323626
Nicotinate phosphoribosyltransferaseHomo sapiens (human)Ki0.00120.00000.00060.0019AID1618606
Transmembrane prolyl 4-hydroxylaseHomo sapiens (human)IC50 (µMol)105.75005.18005.39335.5000AID160197; AID226111
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase Klebsiella pneumoniaeKd1,000.00000.85000.85000.8500AID1320842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
response to oxidative stressNicotinate phosphoribosyltransferaseHomo sapiens (human)
NAD salvageNicotinate phosphoribosyltransferaseHomo sapiens (human)
monoatomic ion transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transportProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transportProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid import across plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proton transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
regulation of erythrocyte differentiationTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
peptidyl-proline hydroxylation to 4-hydroxy-L-prolineTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
nicotinate phosphoribosyltransferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
protein bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
transferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
metal ion bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
amino acid:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
proline:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
protein bindingProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-proline transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
iron ion bindingTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
calcium ion bindingTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
2-oxoglutarate-dependent dioxygenase activityTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
L-ascorbic acid bindingTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
hypoxia-inducible factor-proline dioxygenase activityTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
procollagen-proline 4-dioxygenase activityTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
extracellular regionNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
azurophil granule lumenNicotinate phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
lysosomal membraneProton-coupled amino acid transporter 1Homo sapiens (human)
endoplasmic reticulumProton-coupled amino acid transporter 1Homo sapiens (human)
plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
apical plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
vacuolar membraneProton-coupled amino acid transporter 1Homo sapiens (human)
endoplasmic reticulum membraneTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
endoplasmic reticulumTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (95)

Assay IDTitleYearJournalArticle
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1320842Binding affinity to native signal deficient and TEV cleavage site containing His-tagged Klebsiella pneumoniae OXA-48 expressed in Escherichia coli assessed as dissociation constant by SPR assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID630741Inhibition of human PAT1-mediated L-[3H]proline uptake in human Caco2 cells after 10 mins by liquid scintillation counting2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).
AID323619Inhibition of Stenotrophomonas maltophilia metallo beta lactamase L1 assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID388953Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis and anti-inflammatory structure-activity relationships of thiazine-quinoline-quinones: inhibitors of the neutrophil respiratory burst in a model of acute gouty arthritis.
AID160197Inhibition of prolyl 4-hydroxylase1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Novel inhibitors of prolyl 4-hydroxylase.
AID1605095Inhibition of N-terminal His6-sumo-tagged full length Staphylococcus aureus ClpP expressed in Escherichia coli BL2 (DE3) at 10 uM pre-incubated for 10 mins before Suc-LY-AMC addition and measured after 1 hr by fluorescence based assay relative to control2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Novel Peptidomimetic Boronate ClpP Inhibitors with Noncanonical Enzyme Mechanism as Potent Virulence Blockers
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID388959Toxicity in C57BL/J6 mouse assessed as liver aspartate aminotransferase level2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis and anti-inflammatory structure-activity relationships of thiazine-quinoline-quinones: inhibitors of the neutrophil respiratory burst in a model of acute gouty arthritis.
AID386537Cytotoxicity against human NCI-H23 cells2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
A structural analysis of the differential cytotoxicity of chemicals in the NCI-60 cancer cell lines.
AID323622Inhibition of Aeromonas hydrophila beta lactamase CphA at pH 8.02007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID1848086Antimycobacterial activity against Mycobacterium bovis BCG Pasteur ATCC35734 assessed as inhibition of bacterial growth incubated for 5 days by broth microdilution method2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents.
AID323626Inhibition of Aeromonas hydrophila beta lactamase CphA by competitive inhibition assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID386539Cytotoxicity against human A549 cells2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
A structural analysis of the differential cytotoxicity of chemicals in the NCI-60 cancer cell lines.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID388963Toxicity in C57BL/J6 mouse assessed as creatinine level in serum2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis and anti-inflammatory structure-activity relationships of thiazine-quinoline-quinones: inhibitors of the neutrophil respiratory burst in a model of acute gouty arthritis.
AID1320843Inhibition of native signal containing Klebsiella pneumoniae OXA-48 using nitrocefin substrate pre-incubated for 5 mins before substrate addition2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID323620Inhibition of Legionella gormani beta lactamase metallo FEZ1 expressed in Escherichia coli assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID107915Inhibitory activity against Methionine aminopeptidase 1 from Escherichia coli up to 100 uM concentration; Inactive2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Discovery and structural modification of inhibitors of methionine aminopeptidases from Escherichia coli and Saccharomyces cerevisiae.
AID323614Inhibition of Pseudomonas aeruginosa 101/1477 metallo beta lactamase IMP1 expressed in in Escherichia coli assessed as residual enzyme activity at 100 uM in presence of zinc chloride2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID323621Inhibition of Aeromonas hydrophila beta lactamase CphA at pH 7.02007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID605841Inhibition of Mycobacterium tuberculosis recombinant DXR expressed in Escherichia coli BL21 (DE3) using DXP as substrate and MgCl2 as cofactor at 100 uM preincubated for 10 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies.
AID323618Inhibition of Aeromonas hydrophila metallo beta lactamase CphA assessed as residual enzyme activity at 100 uM in absence of zinc2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID323613Inhibition of Pseudomonas aeruginosa 101/1477 metallo beta lactamase IMP1 expressed in in Escherichia coli assessed as residual enzyme activity at 100 uM in absence of zinc2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID323624Inhibition of Aeromonas hydrophila beta lactamase CphA at pH 10.02007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID1530048Inhibition of Streptococcus pyogenes SrtA deltaN81 mutant expressed in Escherichia coli BL21(DE3) at 100 uM using Abz-LPETA-Dap(Dnp) as substrate preincubated for 10 mins followed by substrate addition measured every min for 2.5 hrs by fluorimetric assay 2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of potential antivirulence agents by substitution-oriented screening for inhibitors of Streptococcus pyogenes sortase A.
AID388961Toxicity in C57BL/J6 mouse assessed as liver alkaline phosphatase level2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis and anti-inflammatory structure-activity relationships of thiazine-quinoline-quinones: inhibitors of the neutrophil respiratory burst in a model of acute gouty arthritis.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID386538Cytotoxicity against human NCI-H522 cells2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
A structural analysis of the differential cytotoxicity of chemicals in the NCI-60 cancer cell lines.
AID388962Toxicity in C57BL/J6 mouse assessed as liver lactate dehydrogenase level2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis and anti-inflammatory structure-activity relationships of thiazine-quinoline-quinones: inhibitors of the neutrophil respiratory burst in a model of acute gouty arthritis.
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID323617Inhibition of metallo beta lactamase VIM4 assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID605761Inhibition of Escherichia coli recombinant DXR using DXP as substrate and MgCl2 as cofactor at 100 uM preincubated for 10 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID323623Inhibition of Aeromonas hydrophila beta lactamase CphA at pH 9.02007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID226111Inhibition of prolyl 4-hydroxylase by chromatographic determination of [14C]-succinic acid on ion-exchange minicolumna1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Novel inhibitors of prolyl 4-hydroxylase. 5. The intriguing structure-activity relationships seen with 2,2'-bipyridine and its 5,5'-dicarboxylic acid derivatives.
AID388952Antiinflammatory activity against human neutrophils assessed as inhibition of PMA-induced superoxide production2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis and anti-inflammatory structure-activity relationships of thiazine-quinoline-quinones: inhibitors of the neutrophil respiratory burst in a model of acute gouty arthritis.
AID605760Inhibition of Escherichia coli recombinant DXR using DXP as substrate and MgCl2 as cofactor preincubated for 10 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies.
AID323616Inhibition of metallo beta lactamase VIM2 assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID1682101Inhibition of bovine adrenal medulla DBH at 0.5 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682100Inhibition of bovine adrenal medulla DBH at 5 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID388960Toxicity in C57BL/J6 mouse assessed as liver alanine aminotransferase level2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis and anti-inflammatory structure-activity relationships of thiazine-quinoline-quinones: inhibitors of the neutrophil respiratory burst in a model of acute gouty arthritis.
AID323627Inhibition of Aeromonas hydrophila beta lactamase CphA N116H-N220G mutant by competitive inhibition assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID323615Inhibition of Bacillus cereus metallo beta lactamase Bc2 assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (616)

TimeframeStudies, This Drug (%)All Drugs %
pre-199061 (9.90)18.7374
1990's98 (15.91)18.2507
2000's203 (32.95)29.6817
2010's192 (31.17)24.3611
2020's62 (10.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 51.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index51.64 (24.57)
Research Supply Index6.58 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index84.39 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (51.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials70 (10.84%)5.53%
Reviews40 (6.19%)6.00%
Case Studies14 (2.17%)4.05%
Observational2 (0.31%)0.25%
Other520 (80.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (17)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of a Table Water Enriched With Amino Acids and Chromium on Blood Glucose and Insulin Levels After a Meal [NCT02487680]20 participants (Actual)Interventional2015-06-30Completed
Influence of an Amino Acid and Chromium Containing Table Water on Glucose Response to a Test Meal in Type 2 Diabetes Patients in a Double Blind Cross - Over Design [NCT02235194]20 participants (Actual)Interventional2014-08-31Completed
The Effect of Co-administered β-Carotene, Vitamin D3, Zinc and Antenatal Steroid Therapy on Hyaline Membrane Disease and Feeding Intolerance in Premature Neonates [NCT03366584]Phase 4120 participants (Anticipated)Interventional2017-01-31Recruiting
Chromium Picolinate in Binge Eating Disorder: A Feasibility Study [NCT00904306]Phase 1/Phase 226 participants (Actual)Interventional2008-07-31Completed
Efficacy and Safety of Chromium as a Therapeutic Intervention for Insulin Resistance Associated With Obesity [NCT00997659]40 participants (Anticipated)Interventional2007-04-30Completed
Novel Therapy for Glucose Intolerance in HIV Disease [NCT02006914]47 participants (Actual)Observational2005-06-30Completed
A Novel Therapy for Glucose Intolerance in HIV Disease [NCT00109746]Phase 1/Phase 239 participants (Actual)Interventional2005-11-30Completed
Effect of Chromium Picolinate on Metabolic and Physiologic Parameters in Type 2 Diabetes [NCT00283777]Phase 430 participants Interventional1998-08-31Completed
Randomized, Double Blinded, Placebo Controlled, Study to Evaluate Improvements in Glycemic Control, Lipid Levels, Quality of Life and Healthcare Costs After Daily Administration of Chromium Picolinate and Biotin in Patients With T2DM [NCT00289354]600 participants Interventional2003-03-31Completed
A Double-Blind Randomized Controlled Clinical Trial of Chromium Picolinate on Clinical and Biochemical Features of the Metabolic Syndrome [NCT00128154]60 participants Interventional2004-01-31Completed
The Effect of Zinc, Beta-carotene, and Vitamin D3 Supplementation as Pro-inflammation Mediated Regulator in Preterm Delivery Through Placental Protein Adaptor MyD88 and TRIF, Transcription Factor NFkB, and Pro-inflammatory Cytokine IL-1β [NCT03005496]Phase 456 participants (Actual)Interventional2017-01-31Completed
Effects of Chromium Picolinate on Food Intake, Satiety, and Eating Attitudes in Overweight Women With Food Cravings [NCT00477854]42 participants (Actual)Interventional2005-04-30Completed
Chromium and Insulin Action [NCT00398853]Phase 4100 participants (Actual)Interventional2003-10-31Completed
"A Randomized, Double Blinded, Placebo Controlled, Parallel Arm, Study to Evaluate the Improvement in Glycemic Control After Daily Administration of Chromium Picolinate and Biotin in Patients With Type 2 Diabetes Mellitus" [NCT00308451]40 participants Interventional2003-11-30Completed
Pilot Trial of Chromium-Metformin Combination in Type 2 Diabetes: Impact on Blood Sugar Control and Insulin Resistance [NCT00332085]Phase 140 participants (Anticipated)Interventional2006-01-31Terminated(stopped due to Issues w/recruitment)
Thinking Zinc: A Study of Zinc Supplementation to Ameliorate Adverse Effects of Mine Waste Exposure on the Navajo Nation [NCT03908736]100 participants (Anticipated)Interventional2019-05-19Recruiting
Can SARS-CoV-2 Viral Shedding in COVID-19 Disease be Reduced by Resveratrol-assisted Zinc Ingestion, a Direct Inhibitor of SARS-CoV-2-RNA Polymerase? A Single Blinded Phase II Protocol (Reszinate Trial) [NCT04542993]Phase 245 participants (Actual)Interventional2020-09-08Terminated(stopped due to Difficulty accruing patients)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]